KyungDong Pharm home
Prescription Medicines

Uronal SR Tab.

Product Category
Treatment for benign prostatic hyperplasia
Active Ingredients
Tamsulosin hydrochloride
Appearance
A white, round tablet.
Reimbursement Code
648101660
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Tamsulosin hydrochloride (JP)----0.2mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: glycerol dibehenate, magnesium stearate, corn starch, hypromellose phthalate

2. Effectiveness
Urination disorder due to benign prostatic hyperplasia

3. Dosage and dosage
Adults: Administer 0.2 mg orally as tamsulosin hydrochloride once a day after a meal.
This medicine should be swallowed whole and should not be crushed or chewed.
Increase or decrease appropriately depending on symptoms.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity (including angioedema) to this drug or its components
2) Patients with orthostatic hypotension (symptoms may worsen)
3) Patients with severe hepatic impairment (plasma concentration may increase)
4) Women who are pregnant or may be pregnant
5) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Administer with caution to the following patients.
1) Patients with severe renal impairment (plasma concentration may increase)
2) Elderly people (refer to the section on administration to elderly people)
3) Patients taking PDE5 (phosphodiesterase-5) inhibitors (see interaction section)
4) Patients taking CYP3A4 inhibitors (see interaction section)
5) Patients taking antihypertensive drugs (refer to the interaction section)
6) In principle, patients taking alpha 1-blockers should not take this drug, but it should be administered with caution only when particularly necessary. (Orthostatic hypotension may occur.)
7) In principle, patients with a history of urinary syncope should not take this drug, but it should be administered with caution only when particularly necessary.

3. Adverse reactions
1) Fainting, loss of consciousness (frequency unknown): Temporary loss of consciousness accompanying a decrease in blood pressure may occur, so observe thoroughly. If any adverse reactions occur, stop administering this drug and take appropriate measures.
2) Mental nervous system: Occasionally, dizziness, abnormal balance, orthostatic dizziness, headache, drowsiness, nervousness, insomnia, decreased libido, nervousness (frequency unknown), and numbness (frequency unknown) may occur.
3) Circulatory system: Occasionally, tachycardia, decreased blood pressure, orthostatic hypotension, palpitations, and arrhythmia may occur.
4) Hypersensitivity reaction: Occasionally rash, itching, and hives may occur. If these symptoms appear, administration should be discontinued.
5) Digestive system: Nausea, vomiting, stomach discomfort, feeling heavy, stomach pain, loss of appetite, dry mouth, constipation, diarrhea, dental problems, and swallowing problems may occur.
6) Liver dysfunction, jaundice (frequency unknown): AST elevation, ALT elevation, jaundice, etc. may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration of this drug, if adverse reactions occur.
7) Others: Occasional burning sensation in the pharyngeal area, general malaise, nasal congestion, nosebleeds, edema, urinary incontinence, dysgeusia, gynecomastia, priapism, infection, lethargy, back pain, chest pain, rhinitis, pharyngitis, increased cough, sinusitis, abnormal ejaculation, amblyopia, intraoperative Floppy Iris Syndrome, blurred vision, visual impairment, Erythema multiforme, exfoliative dermatitis, Stevenson-Johnson syndrome, photosensitivity reaction, and chest discomfort may occur.
8) The adverse reactions that appeared as a result of post-marketing surveillance in foreign countries (USA) are as follows. These are based on voluntary reports, and reliable evaluation of the incidence rate or judgment of causal relationship is not always made. In the United States, the following adverse reactions are included in the precautions for use based on 1) the severity of the adverse reaction, 2) the number of reports, and 3) the degree of causal relationship with this drug.
Skin diseases on the tongue, lips, and face, itching, allergic reactions such as angioedema, urticaria, palpitations, low blood pressure, skin peeling, constipation, vomiting, and rarely priapism have been reported. Additionally, a variant of small pupil syndrome, known as intraoperative iris hypotonia syndrome (IFIS), has been reported during cataract or glaucoma surgery in some patients who are or have previously taken alpha-1-blockers.
※ Domestic post-marketing surveillance results for tamsulosin hydrochloride 0.4mg
As a result of a post-marketing survey conducted on 682 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 10.26% (70/682 people, 77 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to causal relationships are listed in the table below according to frequency of occurrence, and no serious adverse drug reactions for which causal relationships cannot be ruled out were reported.
*Table: refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
*Table: refer to manual

4. General precautions
1) If this drug is administered in excessive amounts, a decrease in blood pressure is expected, so caution should be taken with the dosage.
2) Since blood pressure may decrease when standing up, pay attention to changes in blood pressure due to changes in position.
3) Please note that treatment with this drug is a symptomatic treatment, not a causative treatment. If the expected effect is not obtained from the administration of this drug, other appropriate treatment such as surgery should be considered.
4) Because dizziness may occur, caution should be exercised when engaging in hazardous work such as working at heights or driving a car.
5) In animal experiments, it was reported to exhibit antigenicity when administered in combination with the protein.
6) Prostate cancer and benign prostatic hyperplasia cause similar symptoms, and these two diseases often coexist, so the presence of prostate cancer should be evaluated before administering this drug.
7) The risk of fainting is the same as other alpha 1-blockers.
8) This drug, like other alpha1-blockers, is rarely associated with priapism. Because the condition of priapism can lead to permanent erectile dysfunction if not properly treated, doctors should inform patients of the seriousness of this condition.
9) Intraoperative iris hypotonia syndrome (IFIS) was observed during cataract or glaucoma surgery in some patients who are or have previously taken alpha 1-blockers. Therefore, ophthalmologists should prepare for possible changes in surgical methods such as iris hooks, irish dilator rings, or viscoelastic substances during surgery.
10) Patients with a history of sulfonamide allergy (Cases of allergic reactions to this drug have been reported. If the patient has suffered from a sulfa drug allergy in the past, caution is required when administering this drug.)

5. Interaction
1) Patients taking antihypertensive drugs may have a reduced ability to control blood pressure when standing up, and when used together with antihypertensive drugs, orthostatic hypotension may occur, so be careful about reducing the amount of medication taken.
2) Due to the alpha-blocking effect of this drug, when this drug is administered in combination with a PDE5 inhibitor (sildenafil citrate, vardenafil hydrochloride, etc.), the vasodilator and blood pressure lowering effect of the PDE5 inhibitor may increase. The possibility of hypotension has been reported when coadministering this drug with PDE5 inhibitors.
3) The interaction between anesthetics and other alpha-blockers has not been determined, but interactions are expected and there is a theoretical risk of hypotensive effects.
4) As a result of a study on the interaction with cimetidine, significant changes were observed in the clearance (25% decrease) and AUC (44% increase) of this drug, so caution should be exercised when coadministered with cimetidine (especially when administering a dose of 0.4 mg or more).
5) As the interaction between this drug and warfarin has not reached a definitive conclusion in limited in vitro and in vivo tests, caution should be exercised when using it together.
6) In a pharmacokinetic study conducted on healthy subjects, it was observed that the exposure of this drug may increase when used in combination with a strong CYP3A4 or CYP2D6 inhibitor. When ketoconazole (CYP3A4 inhibitor) was coadministered with 0.4 mg of tamsulosin hydrochloride, the Cmax and AUC of tamsulosin increased by 2.2-fold and 2.8-fold, respectively. In CYP2D6 poor metabolizers, coadministration of tamsulosin hydrochloride with a strong CYP3A4 inhibitor may increase tamsulosin exposure. Because polymorphisms for CYP2D6 are generally unknown, this drug should not be administered with strong CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, indinavir, nelfinavir, ritonavir, saquinavir). Use caution when coadministering tamsulosin hydrochloride with moderate CYP3A4 inhibitors (erythromycin, fluconazole, diltiazem, verapamil). When paroxetine (CYP2D6 inhibitor) was coadministered with 0.4 mg of tamsulosin hydrochloride, the Cmax and AUC of tamsulosin increased by 1.3-fold and 1.6-fold, respectively.

6. Administration to pregnant and lactating women
This drug is not indicated for women. The safety and effectiveness of this drug in women have not been established.

7. Administration to children
This drug is not indicated for children. Safety and efficacy have not been established in children under 18 years of age.

8. Administration to elderly people
Among the elderly, there are patients with decreased renal function, so in these cases, the dose should be started from 0.1 mg and the dose increased to 0.2 mg after sufficient observation. If the expected effect is not achieved with 0.2 mg, the dose should not be increased any further and other appropriate measures should be taken.

9. Application precautions
1) Medicines in PTP packaging are taken out of the PTP packaging. There are reports that if a PTP package is taken, the hard, sharp-angled portion may become lodged in the esophageal mucosa and, in severe cases, perforation may occur, causing serious complications such as mediastinitis.
2) Since this drug is a sustained-release drug, caution patients not to chew it before taking it (extended-release tablets only).

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

11. Others
There was no evidence of fetal harm when administered to pregnant rats at doses up to 300 mg/kg/day (approximately 50 times the human therapeutic dose). There was no evidence of fetal harm when administered to pregnant rabbits at doses up to 50 mg/kg/day.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
100 tablets (10 tablets/Alu-Alu

7. Expiration date
24 months from date of manufacture

Product Updates

Total 6items

No.Product NameDetailsDate of ChangeDownload
6Uronal SR Tab.Precautions for use2024.10.29PDF1_200301609_Euronal extended release tablet_Precautions for use (draft change).pdf
5Uronal SR Tab.Precautions for use2023.02.02PDFEuronal extended-release tablet_Precautions for use.pdf
4Uronal SR Tab.Euronal extended-release tablets (effectiveness, dosage, usage instructions...2013.12.30HWP2012 Pharmaceutical Literature Re-evaluation (Euronal Extended-Release Tablet).hwp
3Uronal SR Tab.Euronal extended-release tablets (precautions for use)2009.10.07HWPEuronal extended release tablet (precautions for use) change (2009.10.12).hwp
2Uronal SR Tab.Euronal extended-release tablets (precautions for use)2008.09.24HWPEuronal extended release tablet (precautions for use) change (2008.09.26).hwp
1Uronal SR Tab.Euronal extended-release tablets (precautions for use)2008.03.18HWPEuronal extended release tablet (precautions for use) change (2008.03.21).hwp